EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lactobacillus delbrueckii subsp. lactis CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice

Hyunsoo Jang iD, Hyunchae Joung iD, Jaeryang Chu, Minseo Cho, Yeon-Woo Kim, Kyung Hwan Kim, Chang Hun Shin iD, Jisu Lee, Jung-Heun Ha iD

Nutrients · 2024

DOI: 10.3390/nu16244260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Hyunsoo Jang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Science and Nutrition, Dankook University, Cheonan 31116, Republic of Korea. Hauptthemen laut MEDLINE: Diet, High-Fat, Obesity, Probiotics, Lactobacillus delbrueckii. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Trade, Industry and Energy, National Research Foundation of Korea (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Functional probiotics, particularly Lactobacillus delbrueckii subsp. lactis CKDB001, have shown potential as a therapeutic option for metabolic dysfunction-associated steatotic liver disease (MASLD). However, their effects have not been confirmed in in vivo systems. Here, we investigated the effects of L. delbrueckii subsp. lactis CKDB001 on insulin resistance, dyslipidemia, MASLD, and lipid metabolism in a murine model of high-fat diet (HFD)-induced obesity.

Methods

The mice were divided into four groups (n = 12 per group)—normal chow diet (NCD), high fat diet (HFD), HFD with L. delbrueckii subsp. lactis CKDB001 (LL), and HFD with resmetirom (positive control (PC), a thyroid receptor β agonist). The experimental animals were fed NCD or HFD for 12 weeks, followed by an additional 12-week oral treatment with LL or resmetirom.

Results

LL supplementation reduced body weight, insulin levels, and HOMA-IR compared with those in the HFD group, indicating improved insulin sensitivity. Additionally, LL reduced serum triglyceride (TG) levels without affecting total cholesterol (TC) levels. HFD consumption increased liver weight and hepatic TG and TC levels, indicating ectopic fat accumulation; however, LL supplementation reversed these changes, indicating a liver-specific effect on cholesterol metabolism. Furthermore, LL administration attenuated NAFLD activity scores, reduced hepatic fibrosis, improved liver function markers (aspartate aminotransferase), and enhanced Adenosine monophosphate-activated protein kinase (AMPK) phosphorylation. However, LL did not considerably affect the expression of genes related to lipid metabolism. In epididymal adipose tissue, LL treatment reduced leptin levels but had no effect on adiponectin; additionally, histological analysis showed an increase in adipocyte size, potentially linked to enhanced energy metabolism.

Conclusions

Collectively, these findings suggest that LL could be a promising therapeutic candidate for improving insulin sensitivity, reducing hepatic lipid accumulation, and mitigating MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, High-FatObesityProbioticsLactobacillus delbrueckiiInsulin ResistanceMice, Inbred C57BLAnimalsMaleMiceLipid MetabolismMice, ObeseLiverDisease Models, AnimalNon-alcoholic Fatty Liver DiseaseDyslipidemias

Stichwörter der Autor:innen

Lactobacillus delbrueckii subsp. lactis CKDB001MASLDprobiotics

Autor:innen und Institutionen

  • Department of Food Science and Nutrition, Dankook University, Cheonan 31116, Republic of Korea.
  • Microbiome Research Laboratory, Chong Kun Dang Bio (CKDBiO) Research Institute, Ansan 15604, Republic of Korea.
  • Chong Kun Dang Bio (CKDBiO) Research Institute, Ansan 15604, Republic of Korea.
  • Research Center for Industrialization of Natural Neutralization, Dankook University, Yongin 16890, Republic of Korea.

ORCID-Profile: Hyunsoo Jang, Hyunchae Joung, Chang Hun Shin, Jung-Heun Ha

Förderung

  • Ministry of Trade, Industry and Energy
  • National Research Foundation of Korea (NRF)

Zitieren

APA

Jang, H., Joung, H., Chu, J., Cho, M., Kim, Y. W., Kim, K. H., Shin, C. H., Lee, J., & Ha, J. H. (2024). Lactobacillus delbrueckii subsp. lactis CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice. Nutrients. https://doi.org/10.3390/nu16244260

Vancouver

Jang H, Joung H, Chu J, Cho M, Kim YW, Kim KH, et al. Lactobacillus delbrueckii subsp. lactis CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice. Nutrients. 2024. doi:10.3390/nu16244260

BibTeX
@article{Jang2024,
  author = {Jang, Hyunsoo and Joung, Hyunchae and Chu, Jaeryang and Cho, Minseo and Kim, Yeon-Woo and Kim, Kyung Hwan and Shin, Chang Hun and Lee, Jisu and Ha, Jung-Heun},
  title = {Lactobacillus delbrueckii subsp. lactis CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16244260}
}
Kostenlos starten →